Health
FDA Authorizes Marketing of Device to Improve Gait in Multiple Sclerosis Patients – FDA.gov
FDA has authorized marketing of a new device intended for use as a short-term treatment of gait deficit due to mild to moderate symptoms from multiple sclerosis
For Immediate Release:
March 26, 2021
Today, the U.S. Food and Drug Administration authorized marketing of a new device indicated for use as a short-term treatment of gait deficit due to mild to moderate symptoms from multiple sclerosis (MS). The device is intended to be used by prescription only as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and older. The device, called Portable Neuromodulation Stimulator (PoNS), is a neuromuscular tongue stimulator that…
-
General18 hours agoGymnastics club in Berwick shuts down following child safety complaint
-
Noosa News21 hours agoSanta drops in for carols
-
General23 hours agoCritically endangered orchid thrives as NSW Mid North Coast cemetery provides habitat refuge
-
Business23 hours agoThe best Australian stock you’ve never heard of